PEG-Peptide Conjugate Equipped with Drug-Interactive Motifs as a Safe and Effective Delivery System for Paclitaxel
P. Zhang,Yixian Huang,Hao Liu,Rebecca T. Marquez,Jianqin Lu,Wenchen Zhao,Xiaolan Zhang,Xiang Gao,Jiang Li,R. Venkataramanan,Liang Xu,Song Li
2014-01-01
Abstract:SUMMARY A novel nanocarrier PEG5K-lysyl-(α-Fmoc-ε-t-Boclysine)2 conjugate (PEG-Fmoc) was developed to provide high loading capacity, excellent formulation stability and low systemic toxicity for paclitaxel (PTX), a first-line chemotherapeutic agent for various types of cancers. 9Fluorenylmethoxycarbonyl (Fmoc) was incorporated as a functional building block to interact with PTX for enhanced carrier-drug compatibility. PTX formulated in PEG-Fmoc micelles demonstrated sustained release kinetics, effective accumulation in tumor sites, a significantly reduced toxicity and improved antitumor activity than Taxol in vivo. INTRODUCTION Micelles are an attractive and well-developed delivery system for a variety of pharmaceutical agents. Most of the current micellar systems are composed of hydrophilic and hydrophobic domains, and drug loading is solely based on the interactions of their hydrophobic domains with the poorly aqueous soluble drugs. While working well for highly hydrophobic agents, these systems have limited effectiveness for moderately hydrophobic drugs due to limited drug-carrier compatibility. We have recently developed a new concept that introduction of a drug-interactive domain at the interfacial region represents an effective strategy to improve the compatibility between lipid-core micelles and the hydrophobic drugs. Among several drug-interactive domains tested, 9-Fluorenylmethoxycarbonyl (Fmoc) was shown to have an unusual propensity in interacting with many types of agents of diverse structure and water solubility. 1, 2 In general, it is believed that a large hydrophobic domain such as a lipid chain or hydrophobic polymer is necessary to construct micelle-forming surfactants. Interestingly, in this study, a novel conjugate without a lipid motif, PEG5K-lysyl-(α-Fmoc-ε-t-Boc-lysine)2 (PEGFmoc), was found to be highly effective in solubilizing PTX. PEG-Fmoc/PTX was further characterized as an effective formulation for PTX in vitro and in vivo. And the potential mechanism involved in the interaction between PEG-Fmoc and PTX was also investigated. EXPERIMENTAL METHODS PEG-Fmoc was synthesized largely following our published method. PTX/PEG-Fmoc mixed micelles were prepared through thin-film hydration method, and the size distribution was examined by dynamic light scattering (DLS). PTX was quantified by highperformance liquid chromatography (HPLC) with a RP18 column equipped with a UV detector at 227 nm. Fluorescence quenching was performed by detecting fluorescence intensity at the excitation wavelength of 270 nm and emission wavelength of 300-460 nm using a Microplate Reader. Drug release kinetics was conducted through a dialysis method. Near infrared fluorescence (NIRF) imaging was performed in SCID mice bearing PC-3 xenografts after i.v. injection of PEG-Fmoc/PTX labeled with Cy5.5, a near infrared fluorescence dye. Mice were scanned with a Carestream Molecular Imaging's In-Vivo Imaging FX Pro at scheduled time points. The maximum tolerated dose (MTD) was determined at a dose of PTX (formulated in PEG-Fmoc or Taxol) given to female BALB/c mice (n=4) via i.v. administration that leads to neither animal death nor significant changes in the general appearance or greater than 15% of body weight loss over 10 days. In vivo therapeutic study was performed by using female BALB/c mice bearing syngeneic mouse breast cancer model (4T1.2). Mice (n=5) were received i.v. injection of saline, Taxol (10 mg PTX/kg), and PTX/PEG-Fmoc (10, 20, and 40 mg PTX/kg) on days 0, 2, 4, 7, 10 and 12, respectively. Tumor volumes were measured by a caliper, and presented as relative tumor volume (the tumor volume at a given time point divided by the tumor volume prior to first treatment). Statistical analysis was performed with two-tailed Student's t-test between two groups, and p<0.05 was considered statistically significant. RESULTS AND DISCUSSION Fmoc is known to provide strong π-π stacking interaction with molecules bearing aromatic rings, and is likely to promote the formation of stable PEG-Fmoc micelles through the Fmoc/Fmoc interaction. PTX may effectively interact with Fmoc, and be encapsulated via Fmoc/PTX π-π stacking interaction (Fig. 1A). As shown in Fig. 1B, PEG-Fmoc readily formed small-sized (25~30 nm) micelles in aqueous solution, and loading of PTX had minimal effect on the size of the particles as determined by DLS. Stable PEG-Fmoc/PTX mixed micelles could be prepared at a PTX loading capacity as high as ~36%, which stands well among the reported PTX micellar formulations. Figure 1. Schematic representation (A) and characterization (B) of PEG-Fmoc/PTX micelles, and demonstration of Fmoc/PTX interaction by fluorescence quenching study (C). Fluorescence quenching study was performed to investigate the mechanism of drug-carrier interaction. A dramatic fluorescence quenching was observed after PTX was loaded into the PEG-Fmoc micelles, and the extent of decrease in fluorescence intensity was correlated to the amount of PTX loaded in micelles (Fig. 1C). This fluorescence quenching is caused by the Fmoc/PTX π-π stacking interaction, which is further supported by the fact that no fluorescence quenching was observed in the hydrophobic interaction between PEG-Fmoc and cholesterol (Chol), a highly model hydrophobic molecule that does not bear aromatic rings. Release kinetics of PTX from PEG-Fmoc/PTX was evaluated via a dialysis method, and Taxol, a clinically used PTX formulation was employed as a comparison. As depicted in Fig 2, Taxol formulation showed a fast release in PBS, pH 7.4 at 37 °C, while PEG-Fmoc/PTX exhibited a sustained release profile, which is likely due to a strong carrier/drug interaction. Figure 2. PTX release kinetics of PEG-Fmoc/PTX and Taxol. Figure 3. In vivo NIRF imaging of tumor-bearing mice after i.v. injection of PEG-Fmoc/Cy5.5-PTX. An effective delivery of PTX to tumor sites was demonstrated by NIRF imaging in tumor-bearing mice (Fig. 3). Cy5.5-PTX was largely found at tumor sites 24 h after i.v. administration of PEG-Fmoc/Cy5.5-PTX, and substantial amounts of signal remained at tumor sites even 96 h later. Consistent with its excellent biophysical properties and tumor-selective delivery, as shown in Fig. 4, PEGFmoc/PTX exhibited an excellent safety profile and significantly enhanced antitumor activity. Even at a dosage as high as 120 mg PTX/kg, neither animal death nor significant weight loss was observed in PEGFmoc/PTX treated group, which is 6-fold higher than the MTD of Taxol. In the therapeutic study, at the same dosage of 10 mg PTX/kg, PEG-Fmoc/PTX was significantly more effective than Taxol in inhibiting the tumor growth (p<0.02). Increasing the PTX dosage was associated with a further enhancement in antitumor activity. Figure 4. Maximum tolerated dose and in vivo therapeutic efficacy of PEG-Fmoc/PTX. (*p<0.02, **p<0.001) CONCLUSION Fmoc/PTX molecular interaction has led to the discovery of PEG-Fmoc as an effective nanomicellar carrier for PTX. This conjugate readily forms small-sized (25-30 nm) micelles with PTX. A strong π-π stacking interaction provides an excellent drug/carrier compatibility with a high loading capacity (~36%). PEGFmoc/PTX effectively and selectively accumulated at tumor tissues, and demonstrated an excellent safety profile and an effective tumor inhibition efficacy in a murine breast cancer model. Our PEG-Fmoc may hold promise as a safe and effective delivery system for PTX with a potential for rapid translation into clinical study.